ArticleNature reviews. Gastroenterology & hepatology2017
Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma.
Article in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Functional Interpretation of Recurrent Genetic Variants in Hepatocellular Carcinoma: Molecular Consequences and Clinical Relevance.Human mutation · 2026Review
- Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.Frontiers in pharmacology · 2024Article
- Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.International journal of molecular sciences · 2023Review
- Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma.Cancer cell international · 2022Review
- The advanced development of molecular targeted therapy for hepatocellular carcinoma.Cancer biology & medicine · 2022Review
- Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.Frontiers in endocrinology · 2022Article
- TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates beta-catenin/TCF signalling.Journal of cellular and molecular medicine · 2021Article
- Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.Gastroenterology · 2021Review
- DNTTIP1 is a Prognostic Biomarker Correlated With Immune Infiltrates in Hepatocellular Carcinoma: A Study Based on The Cancer Genome Atlas Data.Frontiers in genetics · 2021Article
- Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.Cancer communications (London, England) · 2020Review
- Article
- Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- New Therapeutic Targets in Autoimmune Cholangiopathies.Frontiers in medicine · 2020Review
- Integrating Microfabrication into Biological Investigations: the Benefits of Interdisciplinarity.Micromachines · 2019Article
- Dimensions of hepatocellular carcinoma phenotypic diversity.World journal of gastroenterology · 2018Review
- Molecular therapies and precision medicine for hepatocellular carcinoma.Nature reviews. Clinical oncology · 2018Review
- Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults.Clinical therapeutics · 2018Review
- IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.Frontiers in immunology · 2018Article
- Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.Hepatic oncology · 2017Review
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28765583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.